Site-Specific Quantitation of Antibody-Drug Conjugations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of antibody-drug conjugates (ADCs) is hindered by the challenge of achieving well-defined drug-to-antibody ratios (DARs) and homogeneity due to the polyvalent nature of antibodies and non-specific electrophilic reactions, leading to heterogeneous ADC species with variable conjugation sites, which affects drug safety and efficacy.
Innovation Solution
A method involving protease-assisted drug deconjugation and linker labeling (PADDLL) is employed, where a portion of the attachment is cleaved, and a modified linker is added to unconjugated sites, followed by mass analysis using LC-MS to quantify site-specific drug conjugations, ensuring well-defined DARs and homogeneity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If non-specific electrophilic reactions are used for drug-antibody conjugation, then the conjugation process is simple, but the resulting ADCs are highly heterogeneous with variable DARs and conjugation sites
Solution Approach 1:
The invention segments the antibody structure by targeting specific cysteine residues (e.g., in the hinge region) for conjugation, dividing the otherwise uniform conjugation process into site-specific reactions. This allows control over where drugs are attached, reducing heterogeneity while maintaining process simplicity through engineered specificity.
Solution Approach 2:
The invention applies local quality by creating regions of different conjugation density or specificity within the antibody structure. By engineering specific cysteine residues to be more reactive or accessible, the method achieves homogeneous drug attachment at particular locations while leaving other regions unconjugated, thereby defining DAR and conjugation sites precisely.
2Manufacturing precision
If site-specific conjugation methods are implemented to achieve well-defined DARs, then manufacturing precision is improved, but the conjugation process becomes more complex
Solution Approach 1:
The invention applies preliminary action by pre-engineering the antibody with specific cysteine residues that are designed to be selectively reactive. This pre-preparation of the antibody structure eliminates the need for complex post-conjugation purification or characterization steps, as the site-specificity is built into the molecule before the conjugation reaction occurs.
Solution Approach 2:
The invention uses engineered cysteine residues as intermediaries that mediate the conjugation reaction. These specially designed cysteines act as selective attachment points, simplifying the overall process by providing natural, biocompatible reaction sites that require minimal additional reagents or complex reaction conditions compared to non-specific chemical conjugation methods.
3Quantity of substance
If mass analysis is performed on heterogeneous ADC mixtures, then comprehensive characterization is achieved, but measurement precision for site-specific quantitation is reduced
Solution Approach 1:
The invention extracts site-specific information from the heterogeneous ADC mixture by using proteolytic digestion to release peptides containing the conjugation sites. This extraction of specific peptide segments from the complex mixture allows mass spectrometry to focus on measuring only the relevant conjugated peptides, achieving high precision quantitation of site-specific drug attachment while still characterizing the overall ADC population.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise quantitation and characterization of site-specific drug conjugations, improving the quality attributes of ADCs by reducing undesired species, thereby enhancing drug safety and efficacy.
Implementation Method 1
the portion of the attachment is cleaved using papain, cathepsin B or plasmin
Implementation Method 2
subjecting the sample to mass analysis to identify the peptide or protein containing the cleaved linker and/or the modified linker
Data Source
AI summary
A method for site-specific quantitation or characterization of drug conjugations of antibody-drug conjugates using protease-assisted drug deconjugation, linker labelling and mass spectrometry, wherein the conjugation includes an attachment linked to a specific conjugation site of a partially conjugated peptide or protein in a sample. The method comprises cleaving a portion of the attachment to generate the peptide or protein containing a cleaved linker, adding a modified linker to an unconjugated conjugation site of the partially conjugated peptide or protein, and subsequently subjecting the sample to mass analysis to identify the peptide or protein containing the cleaved linker and/or the modified linker.